featured
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
N. Engl. J. Med 2024 Jan 25;390(4)326-337, T Munir, DA Cairns, A Bloor, D Allsup, K Cwynarski, A Pettitt, S Paneesha, CP Fox, TA Eyre, F Forconi, N Elmusharaf, B Kennedy, J Gribben, N Pemberton, O Sheehy, G Preston, A Schuh, R Walewska, L Duley, D Howard, A Hockaday, S Jackson, N Greatorex, S Girvan, S Bell, JM Brown, N Webster, S Dalal, R de Tute, A Rawstron, PEM Patten, P HillmenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.